Inclusion Criteria

Concurrent Medication:

Required:

• PCP prophylaxis.

Allowed:

• Rifabutin, ketoconazole, fluconazole, and acyclovir, provided the medication has been taken for at least 4 weeks prior to study entry without toxicity.
• Topical medications such as clotrimazole troches or nystatin suspension.

Patients must have:

• Documented HIV infection.
• CD4 count <= 350 cells/mm3.
• p24 antigen positive at >= 35 pcg/ml.
• No active opportunistic infection at study entry that would require curative or suppressive therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Malignancy for which systemic chemotherapy is required.
• Medically significant liver disease, orthostatic hypotension, hypertension, cardiac disease, seizure disorders, or lymphoma.
• Any medical condition that would interfere with evaluation of the patient.

Concurrent Medication:

Excluded:

• AZT, ddI, ddC, d4T, or any other antiretroviral medication.
• Interferon or other immunomodulating drugs.
• Cytotoxic chemotherapy.
• Foscarnet.
• Ganciclovir.
• Antimycobacterial drugs other than rifabutin.
• MAO inhibitors.
• Hypertension-inducing, nephrotoxic, or hepatotoxic drugs.
• Opiates.
• Drugs known to cause photosensitivity.

Prior Medication:

Excluded within 1 month prior to study entry:

• AZT, ddI, ddC, d4T, or any other antiretroviral medication.
• Interferon or other immunomodulating drugs.
• Cytotoxic chemotherapy.
• Preparations known to contain hypericin.

Excluded within 3 months prior to study entry:

• Ribavirin.
• Hyperforate (500 mg tablets or ampules for IV injection) manufactured by Kline.
• Psychotonin M Alcohol Extract manufactured by Steigerwald.
• Hypericin (40 mg vial) by VIMRx.

Excluded within 14 days prior to study entry:

• Foscarnet.
• Ganciclovir.
• Antimycobacterial drugs other than rifabutin.
• MAO inhibitors.
• Hypertension-inducing, nephrotoxic, or hepatotoxic drugs.